News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Stevenage Bioscience Catalyst Appoints First Entrepreneur-in-Residence Incubator Also Establishes Experts Panel

12/10/2012 12:30:38 PM

Stevenage, UK, December 10 2012 – Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, has appointed Dr Barbara Domayne-Hayman as its first entrepreneur-in-residence. Dr Domayne-Hayman will work with SBC and its tenants on strategy, as well as new business creation, with an initial focus on cell therapy and neuroscience. She is also a member of the recently established SBC Experts Panel.

Dr Domayne-Hayman is a company builder and deal-maker, who has successfully transitioned from working in large organisations to an entrepreneurial environment. During her time as CEO of Stabilitech Ltd and Commercial Director of Arrow Therapeutics Ltd, she was responsible for multiple agreements, developing teams and bringing in funding. Prior to Arrow, Dr Domayne-Hayman held business positions at Celltech and Zeneca, and consulted for Ernst & Young Strategy Group. She holds a Sloan Fellowship from London Business School, and has a BA and D.Phil in chemistry from the University of Oxford.

The SBC Experts Panel, convened to advise both the incubator and its tenants, comprises over 20 leading professionals active in the biosciences sector. Ranging from chemists and drug development experts to funders, lawyers and finance experts, its members are already actively engaged with the SBC community.

'We are delighted to have appointed Barbara, with her ideal skill set, as our first entrepreneur-in-residence,' said Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst. 'This is an important role in a bioincubator and we look forward to working with her on new opportunities in the biotech and medtech areas. The Experts Panel has made a great start as well, and we will be adding new members as the need arises.'

SBC's Entrepreneur-in-Residence, Dr Barbara Domayne-Hayman, added, 'I've been impressed right from the start by the innovative and dynamic culture Martino and the team have built at SBC, and this is a great opportunity for me to work with them on emerging projects. In common with many people in biotech, one of my aims is to make a real contribution to society through the commercialisation of new science from industry and academia, and SBC is the ideal place to do that.'

Pictures available on request

For more information, please contact:

Stevenage Bioscience Catalyst

Martino Picardo, CEO +44 (0)1438 906906

Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185

About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage bioscience technology and company development, and building a thriving community. It is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board and the former East of England Development Agency. Consisting of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space, the independent facility houses a range of companies, from virtual and start-up firms to those which are more established, as well as other organisations. Located on the GlaxoSmithKline Stevenage site, Stevenage Bioscience Catalyst is in the unique position of operating in proximity to the expertise and resources of a major pharmaceutical company, close to both London and Cambridge. For more information, please go to

About Open Innovation

Firms using Open Innovation (OI) combine their own R&D with externally sourced ideas and expertise. OI is characterised by highly effective use of connections and networks to exchange knowledge and ideas, external partners being involved at all stages of product development, equitable win-win business relationships, and new business models to maximise the value of intellectual property and other assets. Examples in various sectors have shown that the benefits of OI include reduced time to market for new products and services, access to new markets, improved innovation success rates and increased profits. SBC will promote use of Open Innovation within the life sciences sector, connecting SMEs with an active network consisting of GlaxoSmithKline and its other stakeholders, academia, charities, other businesses and funding bodies. The term ‘Open Innovation’ and related research into its practice have been developed extensively by Professor Henry Chesbrough, Executive Director of the Program in Open Innovation at the University of California, Berkeley (

About Stevenage Bioscience Catalyst's stakeholders

Stevenage Bioscience Catalyst's stakeholders are GlaxoSmithKline (, the Wellcome Trust (, the Department of Business, Innovation and Skills (, the Technology Strategy Board ( and the former East of England Development Agency (

Emma Palmer Foster

Strategic Communications Consultant

Stevenage Bioscience Catalyst

m: +44 (0) 7880 787185


Stevenage Bioscience Catalyst

Gunnels Wood Road


Hertfordshire SG1 2FX

Read at

comments powered by Disqus